Literature DB >> 23428928

Response of mucocutaneous lesions to rituximab in a case of melanoma differentiation antigen 5-related dermatomyositis.

Aurélie Clottu1, Emmanuel Laffitte, Christa Prins, Carlo Chizzolini.   

Abstract

We report the first case in Western Europe of a person presenting with dermatomyositis associated with melanoma differentiation antigen 5 antibodies. She sequentially developed severe mucocutaneous erythematous and itchy lesions of the face, scalp, neck, knees and recurrent aphthae. In addition she presented painful, periungual, edematous digital lesions and small ulcers with digital necrosis. Her rapidly evolving, near-fatal interstitial lung disease responded to high-dose intravenous cyclophosphamide. However, her recurrent mucocutaneous manifestations improved only after rituximab administration.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23428928     DOI: 10.1159/000346573

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  7 in total

Review 1.  Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.

Authors:  Kun Huang; Ophir Vinik; Kam Shojania; James Yeung; Rachel Shupak; Michael Nimmo; J Antonio Avina-Zubieta
Journal:  Rheumatol Int       Date:  2019-08-02       Impact factor: 2.631

Review 2.  The Clinical Features of Myositis-Associated Autoantibodies: a Review.

Authors:  Harsha Gunawardena
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

Review 3.  Anti-MDA5 Antibody Spectrum in Western World.

Authors:  Siamak Moghadam-Kia; Chester V Oddis; Rohit Aggarwal
Journal:  Curr Rheumatol Rep       Date:  2018-10-31       Impact factor: 4.592

4.  Effective Administration of Rituximab in Anti-MDA5 Antibody-Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review.

Authors:  Yuka Ogawa; Dai Kishida; Yasuhiro Shimojima; Koichi Hayashi; Yoshiki Sekijima
Journal:  Case Rep Rheumatol       Date:  2017-10-31

5.  Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases.

Authors:  Asmita A Mehta; Tisa Paul; Mithun Cb; Nithya Haridas
Journal:  BMJ Case Rep       Date:  2021-04-28

6.  Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan.

Authors:  Kenichiro Tokunaga; Noboru Hagino
Journal:  Intern Med       Date:  2017-06-01       Impact factor: 1.271

7.  Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review.

Authors:  Chenjia He; Wenyu Li; Qibing Xie; Geng Yin
Journal:  Front Immunol       Date:  2022-01-18       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.